Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: Association with hepatotoxicity

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1591-1595

  Kubota, Masaru ^a   Nakata, Rieko ^a   Adachi, Souichi ^b   Watanabe, Ken Ichiro ^c   Heike, Toshio ^c   Takeshita, Yasufumi ^d   Shima, Midori ^d  

^a NARA WOMEN'S UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Children; Hepatotoxicity; High dose methotrexate; Homocysteine; Methionine; S adenosylhomocysteine

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; BILIRUBIN; FOLINIC ACID; HOMOCYSTEINE; METHIONINE; METHOTREXATE; S ADENOSYLHOMOCYSTEINE; SULFUR; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BURKITT LYMPHOMA; CANCER PATIENT; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; LIVER TOXICITY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; BLOOD; LIVER FUNCTION TEST; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TOXIC HEPATITIS;

ANTIMETABOLITES, ANTINEOPLASTIC; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; HOMOCYSTEINE; HUMANS; LIVER FUNCTION TESTS; MALE; METHIONINE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; S-ADENOSYLHOMOCYSTEINE;

EID: 84903437101     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.850684     Document Type: Article

References (35)

1. Moe PJ, Holen A. High-dose methotrexate in childhood ALL.Pediatr Hematol Oncol 2000 ; 17 : 615-622.
2. Fujita N, Kobayashi R, Takimoto T, et al. Results of the JapanAssociation of Childhood Leukemia Study (JACLS) NHL-98 protocolfor the treatment of B-cell non-Hodgkin lymphoma and matureB-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma2011 ; 52 : 223-229.
3. Mahoney D H J r, Shuster J J, Nitschke R, et al. Acute neurotoxicityin children with B-precursor acute lymphoid leukemia: an associationwith intermediate-dose intravenous methotrexate and intrathecaltriple therapy-a Pediatric Oncology Group study. J Clin Oncol1998 ; 16 : 1712-1722.
4. Rask C, Albertioni F, Bentzen S M, et al. Clinical and pharmacokineticrisk factors for high-dose methotrexate-induced toxicity in childrenwith acute lymphoblastic leukemia-a logistic regression analysis.Acta Oncol 1998 ; 37 : 277-284.
5. Cheng K K. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in childrenwith cancer. Eur J Cancer Care (Engl) 2008; 17: 306-311.
6. Holmboe L, Andersen AM, Mørkrid L, et al. High dose methotrexatechemotherapy: pharmacokinetics, folate and toxicity in osteosarcomapatients. Br J Clin Pharmacol 2012; 73: 106-114.
7. Csordas K, Hegyi M, Eipel OT, et al. Comparison of pharmacokineticsand toxicity after high-dose methotrexate treatments in children withacute lymphoblastic leukemia. Anticancer Drugs 2013; 24: 189-197.
8. Goldman ID, Matherly LH. The cellular pharmacology ofmethotrexate. Pharmacol Ther 1985 ; 28 : 77-102.
9. Jackson RC. Biological Effects of folic acid antagonists withantineoplastic activity. Pharmacol Ther 1984 ; 25 : 61-82.
10. Broxson EH Jr, Stork LC, Allen RH, et al. Changes in plasmamethionine and total homocysteine levels in patients receivingmethotrexate infusions. Cancer Res 1989; 49: 5879-5883.
11. Refsum H, Wesenberg F, Ueland P M. Plasma homocysteinein children with acute lymphoblastic leukemia: changes during achemotherapeutic regimen including methotrexate. Cancer Res1991 ; 51 : 828-835.
12. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003 ; 21 :3084-3091.
13. Valik D, Sterba J, Bajciova V, et al. Severe encephalopathy inducedby the fi rst but not the second course of high-dose methotrexatemirrored by plasma homocysteine elevations and preceded byextreme diff erences in pretreatment plasma folate. Oncology 2005 ;69 : 269-272.
14. Kishi T, Tanaka Y, Ueda K. Evidence for hypomethylation in twochildren with acute lymphoblastic leukemia and leukoencephalopathy.Cancer 2000 ; 89 : 925-931.
15. Cole PD, Beckwith KA, Vijayanathan V, et al. Folate homeostasisin cerebrospinal fl uid during therapy for acute lymphoblastic leukemia.Pediatr Neurol 2009 ; 40 : 34-41.
16. Araki A, Sako Y. Determination of free and total homocysteinein human plasma by high-performance liquid chromatography withfl uorescence detection. JChromatogr 1987 ; 422 : 43-52.
17. She QB, Nagao I, Hayakawa T, et al. Asimple HPLC method for thedetermination of S-adenosylmethionine and S-adenosylhomocysteinein rat tissues: the Effect of vitamin B 6 defi ciency on theseconcentra tions in rat liver. Biochem Biophys Res Commun 1994: 205;1748-1754.
18. Pui C H, Howard S C. Current management and challenges ofmalignant disease in the CNS in paediatric leukaemia. Lancet Oncol2008 ; 9 : 257-268.
19. Schmiegelow K. Advances in individual prediction of methotrexatetoxicity: a review. Br J Haematol 2009 ; 146 : 489-503.
20. Widemann BC, Adamson PC. Understanding and managingmethotrexate nephrotoxicity. Oncologist 2006 ; 11 : 694-703.
21. Hegyi M, Gulácsi A, Cságoly E, et al. Clinical relations ofmethotrexate pharmacokinetics in the treatment for pediatricosteosarcoma. JCancer Res Clin Oncol 2012 ; 138 : 1697-1702.
22. Kim YI. 5, 10-Methylenetetrahydrofolate reductase polymorphismand pharmacogenetics: a new role of single nucleotide polymorphismsin the folate metabolic pathway in human health and disease. Nutr Rev2005 ; 63 : 398-407.
23. Brosnan J T, Brosnan M E. The sulfur-containing amino acids: anoverview. JNutr 2006; 136(6 Suppl.): 1636S-1640S.
24. Roubenoff R, Dellaripa P, Nadeau M R, et al. Abnormalhomocysteine metabolism in rheumatoid arthritis. Arthritis Rheum1997 ; 40 : 718-722.
25. Toffoli G, Russo A, Innocenti F, et al. Effect ofmethylenetetrahydrofolate reductase 677C → T polymorphism ontoxicity and homocysteine plasma level after chronic methotrexatetreatment of ovarian cancer patients. Int J Cancer 2003 ; 103 :294-299.
26. Jabs K, Koury M J, Dupont W D, et al. Relationship between plasmaS-adenosylhomocysteine concentration and glomerular fi ltration ratein children. Metabolism 2006; 55: 252-257.
27. Liu C, Wang Q, Guo H, et al. plasma S-adenosylhomocysteineis a better biomarker of atherosclerosis than homocysteine inapolipoprotein E-defi cient mice fed high dietary methionine. JNutr2008 ; 138 : 311-315.
28. Hagleitner MM, Coenen MJ, Aplenc R, et al. The role of the MTHFR677C-T polymorphism in methotrexate-induced liver toxicity: ameta-analysis in patients with cancer. Pharmacogenomics J 2013May 7. [Epub ahead of print]
29. Kantar M, Kosova B, Cetingul N, et al. Methylenetetrahydrofolatereductase C677T and A1298C gene polymorphism and therapyrelatedtoxicity in children treated for acute lymphoblastic leukemiaand non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 912-917.
30. Kharbanda K K. Alcoholic liver disease and methioninemetabolism. Semin Liver Dis 2009; 29: 155-165.
31. Homung N, Ellingsen T, Stengaard-Pedersen K, et al. Folate, homocysteine, and cobalamin status in patients with rheumatoidarthritis treated with methotrexate, and the Effect of low dose folic acidsupplement. JRheumatol 2004 ; 31 : 2374-2381.
32. Canellos G P, Haskell C M, Arseneau J, et al. Hypoalbuminemicand hypocholesteroemic Effect of L-asparaginase (NSC-109, 229)treatment in man-a preliminary report. Cancer Chemother Rep1969 ; 53 : 67-69.
33. Yalçinkaya S, Unlüçerçi Y, Giris ? M, et al. Oxidative and nitrosativestress and apoptosis in the liver of rats fed on high methionine diet:protective Effect of taurine. Nutrition 2009 ; 25 : 436-444.
34. Lee S J, Kang M H, Min H. Folic acid supplementation reducesoxidative stress and hepatic toxicity in rats treated chronically withethanol. Nutr Res Pract 2011; 5: 520-526.
35. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factoror a powerful marker for cardiovascular diseases? Pathogenetic andtherapeutical uncertainties. JTh romb Th rombolysis 2011; 32: 82-88.